NASDAQ:AGMB

AgomAb Therapeutics (AGMB) Stock Price, News & Analysis

AgomAb Therapeutics logo
$5.44 -0.18 (-3.20%)
Closing price 03:59 PM Eastern
Extended Trading
$5.43 -0.01 (-0.18%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About AgomAb Therapeutics Stock (NASDAQ:AGMB)

Advanced

Key Stats

Today's Range
$5.39
▼
$5.78
50-Day Range
$5.62
▼
$13.06
52-Week Range
$5.39
▼
$17.82
Volume
188,968 shs
Average Volume
155,368 shs
Market Capitalization
$197.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50
Consensus Rating
Moderate Buy

Company Overview

Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis.

The company’s pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-β receptor ALK5 being developed for fibrostenotic Crohn’s disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.

Agomab is headquartered in Belgium and is focused on advancing its therapies through clinical development. Its programs are investigational and have not been established as approved treatments.

AI Generated. May Contain Errors.

AgomAb Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

AGMB MarketRank™: 
3.631196932345 of 5 stars

AgomAb Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 158th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AgomAb Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    AgomAb Therapeutics has a consensus price target of $37.50, representing about 557.9% upside from its current price of $5.70.

  • Amount of Analyst Coverage

    AgomAb Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about AgomAb Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for AgomAb Therapeutics are expected to decrease in the coming year, from ($1.76) to ($1.97) per share.

  • Percentage of Shares Shorted

    2.54% of the float of AgomAb Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    AgomAb Therapeutics has a short interest ratio ("days to cover") of 7.44.
  • Change versus previous month

    Short interest in AgomAb Therapeutics has recently decreased by 2.24%, indicating that investor sentiment is improving.
  • Dividend Yield

    AgomAb Therapeutics does not currently pay a dividend.

  • Dividend Growth

    AgomAb Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    AgomAb Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for AgomAb Therapeutics this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added AgomAb Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Cluster Insider Buying

    3 insiders have purchased shares of AgomAb Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $577,112.00 in company stock, which represents 0.2794% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, AgomAb Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $577,112.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Institutions

    AgomAb Therapeutics has minimal institutional ownership at this time.

  • Read more about AgomAb Therapeutics' insider trading history.
Receive AGMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AgomAb Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AGMB Stock News Headlines

HC Wainwright Has Positive Opinion of AGMB FY2026 Earnings
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
Agomab to Participate in Upcoming Investor Conferences
See More Headlines

AGMB Stock Analysis - Frequently Asked Questions

AgomAb Therapeutics' stock was trading at $15.15 on February 17, 2026. Since then, AGMB shares have decreased by 62.4% and is now trading at $5.70.

AgomAb Therapeutics (AGMB) raised $200 million in an initial public offering on Friday, February 6th 2026. The company issued 12,500,000 shares at $15.00-$17.00 per share.

Shares of AGMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/06/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AGMB
CIK
2020932
Fax
N/A
Employees
62
Year Founded
2017

Price Target and Rating

High Price Target
$60.00
Low Price Target
$28.00
Potential Upside/Downside
+589.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.88
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
36,240,000
Free Float
N/A
Market Cap
$197.15 million
Optionable
N/A
Beta
N/A
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:AGMB) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners